Myelodysplastic Syndromes
"Myelodysplastic Syndromes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
Descriptor ID |
D009190
|
MeSH Number(s) |
C15.378.190.625
|
Concept/Terms |
Myelodysplastic Syndromes- Myelodysplastic Syndromes
- Myelodysplastic Syndrome
- Syndrome, Myelodysplastic
- Syndromes, Myelodysplastic
- Dysmyelopoietic Syndromes
- Dysmyelopoietic Syndrome
- Syndrome, Dysmyelopoietic
- Syndromes, Dysmyelopoietic
Hematopoetic Myelodysplasia- Hematopoetic Myelodysplasia
- Hematopoetic Myelodysplasias
- Myelodysplasia, Hematopoetic
- Myelodysplasias, Hematopoetic
|
Below are MeSH descriptors whose meaning is more general than "Myelodysplastic Syndromes".
Below are MeSH descriptors whose meaning is more specific than "Myelodysplastic Syndromes".
This graph shows the total number of publications written about "Myelodysplastic Syndromes" by people in this website by year, and whether "Myelodysplastic Syndromes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 3 | 5 | 8 |
1995 | 5 | 1 | 6 |
1996 | 7 | 2 | 9 |
1997 | 5 | 5 | 10 |
1998 | 10 | 2 | 12 |
1999 | 6 | 0 | 6 |
2000 | 11 | 0 | 11 |
2001 | 7 | 2 | 9 |
2002 | 18 | 6 | 24 |
2003 | 18 | 6 | 24 |
2004 | 16 | 6 | 22 |
2005 | 14 | 3 | 17 |
2006 | 23 | 6 | 29 |
2007 | 32 | 7 | 39 |
2008 | 30 | 2 | 32 |
2009 | 29 | 5 | 34 |
2010 | 34 | 5 | 39 |
2011 | 49 | 1 | 50 |
2012 | 26 | 1 | 27 |
2013 | 33 | 6 | 39 |
2014 | 48 | 4 | 52 |
2015 | 41 | 3 | 44 |
2016 | 40 | 4 | 44 |
2017 | 37 | 6 | 43 |
2018 | 44 | 3 | 47 |
2019 | 28 | 3 | 31 |
2020 | 37 | 1 | 38 |
2021 | 41 | 4 | 45 |
2022 | 41 | 1 | 42 |
2023 | 33 | 1 | 34 |
2024 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Myelodysplastic Syndromes" by people in Profiles.
-
Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia. Blood Adv. 2024 02 13; 8(3):591-602.
-
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study. Lancet Haematol. 2024 Mar; 11(3):e186-e195.
-
Myelodysplastic neoplasms evolving from inherited bone marrow failure syndromes / germline predisposition syndromes: Back under the microscope. Leuk Res. 2024 Feb; 137:107441.
-
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study. Lancet Haematol. 2024 Jan; 11(1):e15-e26.
-
Fifth Edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissue: Myeloid Neoplasms. Mod Pathol. 2024 Feb; 37(2):100397.
-
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes. Am J Hematol. 2024 Feb; 99(2):E32-E36.
-
Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents. Br J Haematol. 2024 Mar; 204(3):898-909.
-
Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies. Clin Cancer Res. 2023 11 01; 29(21):4352-4360.
-
Current State and Future Prospects of Diagnosis and Management of TP53-Mutated Myeloid Neoplasms. Pathobiology. 2024; 91(1):45-54.
-
Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts. Leukemia. 2023 11; 37(11):2314-2318.